FDA Approved: FOSAPREPITANT DIMEGLUMINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Fosaprepitant Dimeglumine from Hikma Pharmaceuticals USA Inc. under the ANDA program. The submission status is AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• fosaprepitant dimeglumine (fosaprepitant dimeglumine)

Snippet

SUPPL AP for FOSAPREPITANT DIMEGLUMINE (FOSAPREPITANT DIMEGLUMINE)